CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MI

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00162331
Recruitment Status : Completed
First Posted : September 13, 2005
Last Update Posted : April 15, 2011
Information provided by:
Lantheus Medical Imaging

September 9, 2005
September 13, 2005
April 15, 2011
January 2005
July 2007   (Final data collection date for primary outcome measure)
To better understand the interactions between the abnormalities in blood supply from the small vessels of the heart to the heart muscle after a heart attack and the changes in heart size 6 months after the heart attack.
Same as current
Complete list of historical versions of study NCT00162331 on Archive Site
  • To estimate the frequency of residual ischemia as assessed by stress myocardial perfusion imaging (MPI) in patients undergoing primary PCI for AMI.
  • To estimate the 6-month cardiac event rates (composite of death, another heart attack, hospitalization for heart failure, and irregular heart beats requiring treatment).
  • To determine the relationship between changes (from baseline) in LV systolic volume index and LVEF, as measured by gated SPECT imaging 6 months following reperfusion, and the presence and severity of residual ischemia.
  • To measure the performance of angiographic parameters of success of reperfusion therapy (TIMI frame count and TIMI myocardial perfusion grade) in predicting the presence of residual ischemia.
Same as current
Not Provided
Not Provided
CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MI
AIR-MI: Assessment of Ischemia and Remodeling Following Acute Myocardial Infarction
The purpose of this clinical study is to learn if there are any changes in how blood gets to your heart muscle and if your heart size changed after your heart attack.
Not Provided
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Myocardial Infarction
Drug: Technetium Tc99m Sestamibi
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2007
July 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Undergoing primary or rescue PCI for acute MI with ECG evidence of a large territory at risk.

Exclusion Criteria:

  • History of prior MI or CABG surgery, persistent LBBB, Atrial Fibrillation, End stage renal disease, Weight > 350 lbs.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Brazil,   Canada,   United States
Not Provided
Not Provided
Qi Zhu, MD Sr. Medical Director, Lantheus Medical Imaging
Lantheus Medical Imaging
Not Provided
Study Director: Qi Zhu, MD Lantheus Medical Imaging
Lantheus Medical Imaging
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP